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We developed a decision aid (DA) for patients with metastatic non-small cell lung cancer (NSCLC), to better inform patients of their
prognosis and treatment options, and facilitate involvement in decision-making. In a pilot study, 20 patients with metastatic NSCLC
attending outpatient clinics at a major cancer centre, who had already made a treatment decision, reviewed acceptability of the DA.
The median age of the patients was 61 years (range 37–77 years), 35% were male, 20% had a university education, and most (75%)
had English as a first language. Most had received chemotherapy, with 65% currently on treatment. Patients were not anxious at
baseline and had clear understanding of the goals and toxicity of chemotherapy in advanced NSCLC. After reviewing the DA,
patients’ anxiety decreased slightly (P¼0.04) and knowledge scores improved by 25% (Po0.001). Most improvements in
understanding were of prognosis with and without chemotherapy, although patients still believed advanced NSCLC to be curable.
Patients rated the DA highly with respect to information clarity, usefulness and were positive about its use in practice, although 40%
found the prognostic information slightly upsetting. The DA for advanced NSCLC is feasible, acceptable to patients and improves
understanding of advanced NSCLC without increasing patient anxiety.
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Despite advances in treatment for cancer, most patients with
metastatic cancer die of their disease, with life expectancy in the
range of months. Lung cancer is the most common cause of
cancer-related death in North America, with over 200000 cases
diagnosed annually (American Cancer Society, 2006; National
Cancer Institute of Canada, 2006). Whereas cancer treatments for
metastatic disease may prolong life, improve cancer-related
symptoms and cause reduction in tumour size, these effects are
not guaranteed. Some patients benefit from treatment, others do
not. In the case of systemic therapy for non-small cell lung cancer,
the median survival improvement with first-line chemotherapy is
approximately 2 months, although up to 70% of patients may have
symptom improvement (Lopez et al, 1997). Uncertain gains from
treatment must be balanced against the likely occurrence of
treatment-related side effects, which on occasion, can be life-
threatening. Patients who understand their prognosis, treatment
options and the potential benefits and risks of those options can
make informed treatment decisions in accordance with their
personal values.
We developed a decision aid (DA) for patients with
metastatic non-small cell lung cancer, to be used during oncology
consultations, to facilitate decision-making for advanced
lung cancer patients. We then pilot-tested the DA in
patients who had already made a treatment decision for a
preliminary evaluation of its acceptability for use and explored
any potential impact on understanding and anxiety in this
experienced group.
MATERIALS AND METHODS
This study was conducted at a single quaternary cancer centre in
Toronto, Canada, with the approval of the institutional research
ethics board. All study participants provided written informed
consent to participate.
Decision aid development
Information to be presented Based on the required elements of
informed consent (Cassileth et al, 1980), studies of advanced lung
cancer patient information needs (Gamble, 1998; Davidson et al,
1999) and the input of focus groups of advanced lung cancer
patients, the following questions, to be addressed through the DA,
were identified. (1) What is the diagnosis? (2) What is the patient’s
prognosis? (3) What are the treatment options? (4) What are the
benefits, including survival and quality-of-life effects? (5) What are
the potential risks? (6) What is involved for patients pursuing
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sthose options, for example schedules, required investigations and
hospital visits, routes of administration.
Searches of Medline, the Cochrane Collaboration and American
Society of Clinical Oncology websites were performed, (MeSH
terms ‘lung cancer’, ‘non-small cell’, ‘randomized’, ‘randomised’,
‘systematic review’, ‘meta-analysis’). An expert panel of oncolo-
gists and oncology nurses with lung cancer expertise reviewed and
identified standard treatment options accepted by the lung
oncology community. Three meta-analyses of trials comparing
chemotherapy with supportive care (one updated) (Souquet et al,
1993; Marino et al, 1994; Non-small Cell Lung Cancer Collabora-
tive Group, 1995; Non-small Cell Lung Cancer Collaborative
Group, 2000), and three systematic reviews were identified (Lopez
et al, 1997; Sorenson et al, 2001; Paesmans, 2002). No additional
randomised trials of first-line chemotherapy vs supportive care
were identified. Information on the survival impact of first-line
chemotherapy and the effects on quality of life were incorporated
into the DA. By patient request, survival and quality of life data
from current randomised trials using newer generation chemo-
therapy were also presented. Data on toxicity of commonly
used regimens in the institution were derived from multicentre
randomised trials (Kelly et al, 2001; Schiller et al, 2002). The DA
incorporated options of supportive care þ/  systemic therapy
and clinical trial participation. To help patients integrate their
values into the decision-making process, the ‘weigh scale’
values clarification exercise, developed by O’Connor et al.
(1995), was adapted for use by lung cancer patients and
incorporated into the DA.
Presentation format Presentation format was informed by the
National Health and Medical Research Council guidelines on
presenting evidence to consumers (National Health and Medical
Research Council, 1999), current literature (Brundage et al, 2005)
and focus groups of patients and caregivers. The DA was designed
as a 25-page booklet (letter-sized paper) with treatment options,
toxicity and survival information illustrated in graphic (as well as
numeric and verbal) format for use during the consultation, which
patients could then take home, with an audiorecording. An
adaptation of Quality-adjusted Time Without Symptoms and
Toxicity (Q-TwiST, Gelber et al, 1993) was used to illustrate the
concept of the trade off between treatment toxicity and potential
gains from therapy. Additional information presented included
colour-coded calendar schedules of treatment days and days of
most likely toxicity (as advised by the expert panel and patient
experiences, where possible), a flowchart of different treatment
pathways and a list of references. Relevant clinical trials available
at the Princess Margaret Hospital with their purpose, design and
study sponsors were included, as well as a guide to support and
information services. The reading level of the DA was grade 7.8,
using the Flesch-Kincaid method (Microsoft Word, Microsoft
Corp., Redmond WA, USA).
Pilot-testing in advanced lung cancer patients
Consecutive patients attending outpatient thoracic oncology
clinics at the Princess Margaret Hospital over 4 months were
invited to participate in the study after approval by their
oncologist and provision of written consent to participate.
Inclusion criteria for participation were: (1) diagnosis of metastatic
non-small cell lung cancer; (2) age 18 years or older and (3) first-
line systemic treatment decision had already been made. Patients
were excluded if they were (1) deemed inappropriate by the
treating physician for reasons of well-being or anxiety, (2) non-
English speaking, (3) undergoing a change in treatment and (4)
unable to provide informed consent.
Demographic data were collected by self-report on all patients
including age, gender, marital status, occupation, educational level,
first language, country of origin, time since diagnosis of metastatic
disease and history of prior therapy. Patients were invited to
review the in-consultation diagrams and booklet through a
structured interview. Feasibility and acceptability, including the
amount, length and clarity of information, and usefulness of the
DA, were assessed by a 10-item questionnaire adapted from Fiset
et al. (2000) and Barry et al. (1995) to assess acceptability of shared
decision-making programmes. Patient anxiety, as another measure
of acceptability of the aid, and knowledge were measured using a
pre-/post-test design, using the 20-item State-Trait Anxiety
Inventory (STAI Form Y) and a 16-item scale adapted from Fiset
et al. (2000) and Brundage et al. (2001). Oncologists were also
invited to review the DA and assess feasibility and content validity.
Statistical analysis Frequency data on demographics, feasibility
and acceptability were summarised, and pre-/post-anxiety and
knowledge scores were compared using a paired samples t-test
(SPSS Statistical Package). The impact of demographic variables
on knowledge scores (gender, educational attainment, English-
speaking background, age, prior chemotherapy and baseline
anxiety), was explored through w
2analyses.
RESULTS
Twenty patients with Stage IV NSCLC were invited to participate,
and all consented. Eight patients were screened by research staff
and deemed too unwell to participate. No patient was excluded by
their physician for anxiety. All were able to review the DA within
25min (range 15–25min). The median age of patients was 61
years (range 37–77 years), 35% were male, 20% had a university
education and most (75%) had English as a first language (see
Table 1). All but one had received chemotherapy, with 65%
currently on treatment. After reviewing the aid, 90% felt strongly
that they would choose chemotherapy, (if they were to choose
again). The patient who had never received treatment was unsure
and another who had previously received chemotherapy was
leaning towards supportive care alone.
Table 1 Sample characteristics (n¼20)
Age
Median 61 years
Range 37–77 years
X65 years 8 (40%)
Gender
Male 7 (35%)
Female 13 (65%)
Marital status
Married 14 (70%)
Widowed 4 (20%)
Divorced 1
Single 1
Education
High school 6 (30%)
College 10 (50%)
University 4 (20%)
Occupation
Professional 4 (20%)
Paraprofessional 4 (20%)
Clerical 10 (50%)
Labourer 2 (10%)
English as first language 15 (75%)
Prior medical or allied health training 3 (15%)
Prior chemotherapy 19 (95%)
Treatment ongoing 13 (65%)
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information and usefulness and felt treatment options were
presented in a balanced manner. Nineteen (95%) rated everything
as clear, one (5%) rated most things as clear; sixteen (80%) rated
the DA as very useful and four (20%) as somewhat useful. Most
(95%) felt they would have benefited from using the DA in their
own treatment decision. All were positive about using the aid,
although 40% found the prognostic information slightly upsetting,
but anxiety as measured by the STAI did not increase (see Table 2).
Patient feedback suggested that although information about
treatment benefit is important, the maintenance or promotion of
hope despite the prognosis of advanced NSCLC is essential to
patients.
Patients were not anxious at baseline (median score 29, range
21–43, maximum possible score 80). After reviewing the DA,
patient anxiety decreased slightly (tdf19  2.199, P¼0.04). They had
clear understanding of the goals and toxicity of chemotherapy in
advanced NSCLC prior to reviewing the DA, as expected in a group
of experienced patients, and this improved by 25% after reviewing
the aid (median 4 of 16 items, tdf19 6.472, Po0.001). Most
improvements in understanding related to prognosis with and
without chemotherapy, and supportive care. Despite an explicit
statement that current chemotherapy options for metastatic
disease were not offered with curative intent, all patients reported
that metastatic NSCLC was curable after reviewing the DA. There
was no impact of demographic variables on knowledge (gender,
educational attainment, English-speaking background, age, prior
chemotherapy and baseline anxiety).
DISCUSSION
This DA, developed to assist patients with advanced NSCLC
considering first-line chemotherapy during and after their initial
oncology consultation, is feasible, highly acceptable to patients and
improves understanding. In this experienced group of patients, the
aid helped to add additional information to their current under-
standing of their illness and did not significantly increase their
anxiety, suggesting that the DA may be an acceptable and highly
informative tool for newly diagnosed patients, to be evaluated in
subsequent trials. All but one patient reported that they would
have liked to have reviewed the DA prior to their own treatment
decision. Many patients and their families want detailed informa-
tion about their diagnosis, prognosis, treatment options and to be
active participants in the decision-making process (Lobb et al,
1999). Involving patients in decision-making may contribute to
better health outcomes. However, to be active participants,
patients must have accurate information about their illness and
treatment options. Whereas internet use has greatly enhanced
patient’s access to healthcare information, it can be inaccurate or
misleading or taken out of the relevant medical context (Wyatt,
1997; Jadad and Gagliardi, 1998). Despite efforts to ensure
informed decision-making, it is often incomplete. Oncologists do
discuss the goals of systemic therapy with advanced cancer
patients, as well as its impact on prognosis and side effects.
However, in an analysis of 118 audio-taped oncology consultations
with advanced cancer patients, fewer oncologists discuss life
expectancy, the patient’s treatment preference and alternatives,
such as supportive care alone (Gattellari et al, 2002). The impact of
treatment on patient’s quality of life was discussed in only one-
third of consultations, and oncologists checked for patient
understanding of information in only 10%. Even when all relevant
information is discussed with their oncologists, as many as a third
of patients misunderstand this information (Gattellari et al, 1999).
This should not surprise oncologists, given the amount and
complexity of information to review, the anxiety and distress
associated with a diagnosis of advanced cancer and possible
coping strategies, such as denial. As denial is an important
contributor to patient’s misunderstanding, the clarity of informa-
tion received from the oncologist is also predictive of under-
standing. Many patients with advanced disease overestimate their
prognosis, and more than half are clearly overoptimistic. For
example, Weeks et al, (1998) found in a large study of inpatients
with advanced cancer that 58% were overly optimistic about their
prognosis compared to their physician . These patients were much
more likely to request aggressive medical interventions, although
their survival was not improved when compared to those who did
not pursue aggressive care. In our study, patients failed to report
that the goal of treatment was not cure, despite enhanced
understanding of potential outcomes and toxicities of systemic
therapy after reviewing the DA. It is unclear whether this
represents patient denial, misunderstanding of the DA or even
misunderstanding of the question asked. Perhaps, rather than a
lack of understanding, this is a measure of patient hope, such as
the potential for curative therapy to be developed in the future, or
even the existence of miracles.
As many as 18% of advanced cancer patients in the United States
are receiving chemotherapy within 14 days of death, a number that
is increasing over time (Earle et al, 2004). Although misunder-
standing or denial may contribute to this phenomenon, there are
alternate explanations. Cancer patients’ valuation of therapeutic
Table 2 Acceptability of the DA (n¼20)
N (%)
Amount of Information
About right 17 (85%)
Little more than wanted 3 (15%)
Lot more than wanted 0
Little less than wanted 0
Lot less than wanted 0
Length of DA
About right 12 (60%)
Little too long 6 (30%)
Much too long 2 (10%)
Information clarity
Everything clear 19 (95%)
Most things clear 1
Helpfulness
Very helpful 15 (75%)
Helpful 5 (25%)
Balance between options
Balanced 16 (80%)
Slight slant toward chemotherapy 3 (15%)
Appropriateness of DA
Very appropriate 16 (80%)
Somewhat appropriate 4 (20%)
Usefulness
Very useful 16 (80%)
Somewhat useful 4 (20%)
How do you feel about DA?
Very positive 9 (45%)
Generally positive 11 (55%)
Was the information upsetting?
Not upsetting 12 (60%)
Slightly upsetting 8 (40%)
Would you like to have seen before you made your decision?
Definitely yes 11 (55%)
Yes 8 (40%)
Perhaps 1
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et al, 2006). Even the well-informed patient may seek aggressive
therapy for small gains despite toxicity, which may also contribute
to the increase in aggressive end-of-life care. Our study confirms
the findings of Matsuyama et al. (2006) that receiving realistic
information about prognosis is difficult in the setting of advanced
cancer. Despite this, it remains important that patients are well
informed about their prognosis and realistic outcomes of available
treatments, to ensure that their decisions are in keeping with their
personal values.
Other DAs for advanced NSCLC patients have been developed.
Fiset et al. (2000) developed a workbook and an audiotape for
metastatic NSCLC patients to take home post-consultation. The aid
has been shown to improve patients’ knowledge of options and
outcomes and reduce decisional conflict. But despite only limited
discussion of prognosis with and without chemotherapy, this did
upset some patients. Brundage et al. (2001) developed an aid using
a structured interview to help patients work through trade off
exercises to clarify their values for the outcomes of median
survival and 1-year or 3-year survival with the addition of
chemotherapy to supportive care. Although the majority of
patients were able to complete the exercises, this approach may
be limited in clinical practice by the amount of time and dedicated
personnel required. In the current study, we have developed an aid
with additional prognostic information, and connected it to the
physician encounter, by including diagrams the health care team
can use when reviewing treatment options and chemotherapy
teaching in the consultation.
The potential benefits of DAs for cancer patients include
enhanced achievement of their information needs, greater under-
standing of the treatment options, goals, benefits and risks, and
greater involvement in their treatment decision-making and
cancer care. A meta-analysis of randomised trials of DAs in
medicine found that their use produces higher knowledge scores,
lower decisional conflict and more active patient participation in
decision-making (O’Connor et al, 1999). To assess the impact, this
DA may have on patient treatment decisions and the decision-
making process, a randomised trial is needed. The current pilot
study in experienced NSCLC patients, many of whom received
chemotherapy, confirms the potential of this tool to enhance
current education about advanced NSCLC therapy, despite
potential bias in the pilot study sample.
In the setting of advanced cancer, DAs may facilitate the
introduction of supportive or palliative care, discussion of life
expectancy and setting realistic expectations for treatment out-
comes. However, a key challenge for DAs in advanced cancer is to
promote or sustain hope, when the goal of treatment is not cure.
Despite evolution in the management of advanced NSCLC,
progress is slow and treatment outcomes for the majority remain
poor. The protection of hope without promoting confusion
in advanced NSCLC remains a challenge for patient and
oncologist alike.
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